FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHI

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* WALTON ALAN G (Last) (First) (Middle) 315 POST ROAD WEST						Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD] 3. Date of Earliest Transaction (Month/Day/Year) 06/10/2005									appliorector ficer low)	(give title Otl bel		10% Ov Other (s below)	vner	
(Street) WESTP(WESTPORT CT 06880				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						xecution any	Deemed ecution Date, ny onth/Day/Year)		Transaction Dispo		rities Acquired (A) ed Of (D) (Instr. 3, 4		and Securiti		es Fo ially (D) Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Pr		Tra	Transaction(s) (Instr. 3 and 4)				instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															•					
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution D y or Exercise (Month/Day/Year) if any			Date, Transac Code (I					6. Date Ex Expiration (Month/Da	Date	Amount of		f s g Securit	8. Pric Deriva Securi (Instr.	ive	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	ode ,	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$8.85	06/10/2005			A		6,500		(1)	C	06/09/2015	Common Stock	6,500) \$0		6,500		D		
Stock Option (Right to	\$8.85	06/10/2005			A		5,084		(1)	0	06/09/2015	Common Stock	5,084	4 (2)		5,084		D		

Explanation of Responses:

- 1. One-fourth of the shares subject to the Stock Option shall vest and become exercisable at the end of each 3 month period following the date of grant.
- 2. The Reporting Person has elected to convert his annual retainer of \$15,000 into a stock option under the terms of the Issuer's 2004 Non-Employee Directors' Stock Option Plan.

/s/ Raymond Charest, 06/14/2005 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Raymond Charest, Alexia Pearsall and Jonathan J. Fleming, and each of them, with full power to act without the other, his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities (until revoked in writing) to sign any and all instruments, certificates and documents required to be executed on behalf of himself as an individual or in his capacity as a general partner or authorized signatory, as the case may be, on behalf of any of Oxford Bioscience Partners IV L.P., mRNA II L.P., or OBP Management IV $\,$ L.P., pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the By-laws of the National Association of Securities Dealers, Inc., granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary fully to all intents and purposes as he might or could do in person thereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof, or may have done in connection with the matters described above.

IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 8th day of April, 2004.

OXFORD BIOSCIENCE PARTNERS IV L.P. by its General Partner, OBP MANAGEMENT IV L.P.

By: /s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

MRNA FUND II L.P. By its General Partner, OBP MANAGEMENT IV L.P.

By: /s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

OBP MANAGEMENT IV L.P.

By:/s/ Jonathan Fleming Name: Jonathan J. Fleming Title: General Partner

/s/ Jeffrey T. Barnes Jeffrey T. Barnes

/s/ Mark P. Carthy Mark P. Carthy

/s/ Jonathan J. Fleming Jonathan J. Fleming

/s/ Michael E. Lytton Michael E. Lytton

/s/ Alan G. Walton Alan G. Walton